Contineum Therapeutics (NASDAQ:CTNM) Upgraded at Baird R W

Contineum Therapeutics (NASDAQ:CTNM) was upgraded by equities research analysts at Baird R W to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

CTNM has been the topic of a number of other reports. Robert W. Baird initiated coverage on shares of Contineum Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $32.00 price target on the stock. Royal Bank of Canada raised their target price on shares of Contineum Therapeutics from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Wednesday, August 14th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Contineum Therapeutics has an average rating of “Buy” and an average target price of $29.50.

Contineum Therapeutics Trading Down 0.1 %

Shares of CTNM stock opened at $16.26 on Tuesday. Contineum Therapeutics has a 12 month low of $13.27 and a 12 month high of $22.00. The stock has a 50-day moving average price of $17.98 and a 200 day moving average price of $17.64.

Contineum Therapeutics (NASDAQ:CTNM) last released its earnings results on Tuesday, August 13th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.02). Equities analysts forecast that Contineum Therapeutics will post -2.04 EPS for the current fiscal year.

Institutional Trading of Contineum Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Johnson & Johnson acquired a new position in shares of Contineum Therapeutics during the 2nd quarter worth about $34,853,000. Perceptive Advisors LLC acquired a new position in shares of Contineum Therapeutics during the 2nd quarter worth about $27,589,000. Versant Venture Management LLC bought a new position in Contineum Therapeutics during the second quarter worth about $16,169,000. Squarepoint Ops LLC bought a new stake in Contineum Therapeutics in the second quarter valued at approximately $2,642,000. Finally, Driehaus Capital Management LLC acquired a new position in shares of Contineum Therapeutics during the 2nd quarter worth approximately $1,174,000.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).